Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

Sermonix Pharmaceuticals, a US-based biopharmaceutical company focused on metastatic breast and gynaecological cancers, has completed a $40m series A3 round led by Perceptive Advisors’ Xontogeny Ventures Fund II. The round included unnamed existing backers. Sermonix, which is based on research at Duke University, previously disclosed $26m in series A financing led by the Wild Family…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).